Unaudited Financial Statement alongwith LRR for the Quarter ended on 30th June, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Denis Chem Lab reported Q1 FY26 revenue from operations of Rs 4,327.59 lakhs, up about 4.9% from Rs 4,125.74 lakhs in the same quarter last year. Total income rose to Rs 4,357.61 lakhs versus Rs 4,158.23 lakhs a year ago. Profit after tax jumped to Rs 247.50 lakhs from Rs 207.63 lakhs, a growth of around 19% year-on-year, helped by lower other expenses and stable finance costs. Earnings per share stood at Rs 1.78 versus Rs 1.78 earlier, though the comparison shows Rs 1.50 in Q1 FY25 (now restated). The statutory auditors Shah & Shah Associates issued an unmodified limited review report with no qualifications. The company has no outstanding loans or debt as on date and operates in a single segment of transfusion solutions in bottles.
A clean auditor opinion with zero debt and steady mid-teens profit growth signals a financially stable small-cap pharma company. For shareholders, this is a routine, positive quarterly update with no red flags, though revenue growth remains modest at under 5%.